Version 1
: Received: 17 January 2024 / Approved: 18 January 2024 / Online: 18 January 2024 (13:53:00 CET)
How to cite:
Sava, A.; Lupascu, F. G.; Tătărușanu, S.-M.; Iacob, A.-T.; Dascălu, A.; Profire, B.-Ș.; Vasincu, I.-M.; Apotrosoaei, M.; Profire, L. Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints2024, 2024011399. https://doi.org/10.20944/preprints202401.1399.v1
Sava, A.; Lupascu, F. G.; Tătărușanu, S.-M.; Iacob, A.-T.; Dascălu, A.; Profire, B.-Ș.; Vasincu, I.-M.; Apotrosoaei, M.; Profire, L. Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints 2024, 2024011399. https://doi.org/10.20944/preprints202401.1399.v1
Sava, A.; Lupascu, F. G.; Tătărușanu, S.-M.; Iacob, A.-T.; Dascălu, A.; Profire, B.-Ș.; Vasincu, I.-M.; Apotrosoaei, M.; Profire, L. Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints2024, 2024011399. https://doi.org/10.20944/preprints202401.1399.v1
APA Style
Sava, A., Lupascu, F. G., Tătărușanu, S. M., Iacob, A. T., Dascălu, A., Profire, B. Ș., Vasincu, I. M., Apotrosoaei, M., & Profire, L. (2024). Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy. Preprints. https://doi.org/10.20944/preprints202401.1399.v1
Chicago/Turabian Style
Sava, A., Maria Apotrosoaei and Lenuta Profire. 2024 "Simultaneous Determination of Pioglitazone and Curcumin from Chitosan-Based Co-delivery Nanosystem for Diabetes Mellitus Therapy" Preprints. https://doi.org/10.20944/preprints202401.1399.v1
Abstract
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders, with a major involvement of oxidative stress in its onset and progression. Pioglitazone (Pio) is an antidiabetic drug which primarily works by reducing insulin resistance while Curcumin (Cur) is powerful antioxidant with o important hypoglycemic effect, also. The both drugs are associated with several drawbacks, such as reduced bioavailability, a short half-life time (Pio) as well as instability and poor water solubility (Cur), which limit their therapeutic use. In order to overcome these disadvantages, a new co-delivery (Pio, Cur) nanosystem based chitosan (CS) (CS-Pio-Cur NPs), was developed, and characterized in reference with simple nanosystems (CS-Pio NPs, CS-Cur NPs). The developed CS-based NPs (CS-Pio-Cur NPs, CS-Pio NPs, CS-Cur NPs) were physico-chemical characterized in terms of particle size (PS), entrapment efficiency (EF%) and loading capacity (LC%). The CS-Pio-Cur NPs proved increased or similar values of EE (88.95% ± 7.79 for Cur; 94.83% ± 9.89 for Pio) and LC% (24.25 % ± 1.62 for Cur; 3.5% ± 0.98 for Pio), in reference with simple nanosystems, CS-Cur NPs (EE = 82.46% ± 1.74; LC = 20.34% ± 0.94) and CS-Pio NPs) (EE = 96.31% ± 0.68; LC = 4.11% ± 0.47), respectively. The identification of APIs (Cur, Pio) loaded into CS matrix was performed using FR-IR spectroscopy and for simultaneously quantification of APIs (Cur, Pio) released from CS-Pio-Cur NPs, a HLPC method was developed and validated. Based on release study performed in different simulated fluids (SGF, SIF, SCF) it can be appreciated that developed CS-APIs NPs have favorable pharmacokinetic profile with good release in gastrointestinal tract.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.